Biotech Values

[jq1234]

I listened to two of them, MITI and AVEO, plan to listen to PCYC. I got new items from question and answer session. For example,

1. MITI to present full MT103 NHL data at ICML June 15-18.
2. AVEO phase III RCC trial design assumption: PFS nexavar 6.1m, tivzanib 9.1m, statistical power 90%. It's great company discloses this type of information.